Fengyuan Y. Che

308 Ningxia Street
Qingdao, 266071, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 122 publications

Baicalin-loaded MOF-818 nanozyme for ischemic stroke treatment via ROS scavenging and neuroinflammation suppression.

Baicalin-loaded MOF-818 nanozyme for ischemic stroke treatment via ROS scavenging and neuroinflammation suppression.

Journal: Biomedical materials (Bristol, England)

Published: August 07, 2026

Retraction notice to "Arctigenin attenuates ischemic stroke via SIRT1-dependent inhibition of NLRP3 inflammasome" [Biochem. Biophys. Res. Commun. 493 (2017) 821-826].

Retraction notice to "Arctigenin attenuates ischemic stroke via SIRT1-dependent inhibition of NLRP3 inflammasome" [Biochem. Biophys. Res. Commun. 493 (2017) 821-826].

Journal: Biochemical and biophysical research communications

Published: July 31, 2026

The translational potential of drug-induced hypothermia in acute ischemic stroke.

The translational potential of drug-induced hypothermia in acute ischemic stroke.

Journal: Science translational medicine

Published: June 17, 2026

Discovery of aloe-emodin as an antidepressant agent by targeting RANBP9.

Discovery of aloe-emodin as an antidepressant agent by targeting RANBP9.

Journal: Molecular diversity

Published: May 08, 2026

Intravenous Tenecteplase Prior to Endovascular Treatment for Ischemic Stroke at 4.5 to 24 Hours: The TNK-PLUS Randomized Clinical Trial.

Intravenous Tenecteplase Prior to Endovascular Treatment for Ischemic Stroke at 4.5 to 24 Hours: The TNK-PLUS Randomized Clinical Trial.

Journal: JAMA

Published: May 08, 2026

Licochalcone a Disrupted Mitochondrial Function to Promote Cuproptosis in Glioblastoma Through Regulating RAS/MAPK Pathway.

Licochalcone a Disrupted Mitochondrial Function to Promote Cuproptosis in Glioblastoma Through Regulating RAS/MAPK Pathway.

Journal: Applied biochemistry and biotechnology

Published: May 02, 2026

Thrombolysis-to-Puncture Time Determines the Differential Effect of Tenecteplase Versus Alteplase in Large Vessel Occlusion.

Thrombolysis-to-Puncture Time Determines the Differential Effect of Tenecteplase Versus Alteplase in Large Vessel Occlusion.

Journal: Stroke

Published: April 09, 2026

Infarct growth rate and tenecteplase benefit in ischemic stroke at 4.5 to 24 h without thrombectomy-A secondary analysis of the TRACE-III randomized trial.

Infarct growth rate and tenecteplase benefit in ischemic stroke at 4.5 to 24 h without thrombectomy-A secondary analysis of the TRACE-III randomized trial.

Journal: International journal of stroke : official journal of the International Stroke Society

Published: April 07, 2026

Infarct Growth Rate and Tenecteplase Benefit in Ischemic Stroke at 4.5 to 24 Hours Without Thrombectomy --A Secondary Analysis of the TRACE-Ⅲ Randomized Trial.

Infarct Growth Rate and Tenecteplase Benefit in Ischemic Stroke at 4.5 to 24 Hours Without Thrombectomy --A Secondary Analysis of the TRACE-Ⅲ Randomized Trial.

Journal: International journal of stroke : official journal of the International Stroke Society

Published: April 07, 2026

Ticagrelor with aspirin dual antiplatelet therapy combined with intravenous thrombolysis in patients with ischaemic stroke in China (TAPIS): a multicentre, double-blind, randomised controlled trial.

Ticagrelor with aspirin dual antiplatelet therapy combined with intravenous thrombolysis in patients with ischaemic stroke in China (TAPIS): a multicentre, double-blind, randomised controlled trial.

Journal: Lancet (London, England)

Published: March 23, 2026

Clinical benefit of tenecteplase despite failed recanalization in late-window ischemic stroke: a post hoc analysis of the TRACE-3 trial.

Clinical benefit of tenecteplase despite failed recanalization in late-window ischemic stroke: a post hoc analysis of the TRACE-3 trial.

Journal: BMC medicine

Published: December 23, 2025

Tenecteplase versus standard medical treatment for basilar artery occlusion within 24 h (TRACE-5): a multicentre, prospective, randomised, open-label, blinded-endpoint, superiority, phase 3 trial.

Tenecteplase versus standard medical treatment for basilar artery occlusion within 24 h (TRACE-5): a multicentre, prospective, randomised, open-label, blinded-endpoint, superiority, phase 3 trial.

Journal: Lancet (London, England)

Published: November 06, 2025

Showing 1-12 of 122

Last Updated: 09/26/2026